MA40880A - Éradication guidée par l'arn du virus jc humain et d'autres polyomavirus - Google Patents
Éradication guidée par l'arn du virus jc humain et d'autres polyomavirusInfo
- Publication number
- MA40880A MA40880A MA040880A MA40880A MA40880A MA 40880 A MA40880 A MA 40880A MA 040880 A MA040880 A MA 040880A MA 40880 A MA40880 A MA 40880A MA 40880 A MA40880 A MA 40880A
- Authority
- MA
- Morocco
- Prior art keywords
- polyomaviruses
- eradication
- rna
- virus
- guided
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
- C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462072927P | 2014-10-30 | 2014-10-30 | |
| US201562169390P | 2015-06-01 | 2015-06-01 | |
| US201562169638P | 2015-06-02 | 2015-06-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40880A true MA40880A (fr) | 2017-09-05 |
Family
ID=55858408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA040880A MA40880A (fr) | 2014-10-30 | 2015-10-29 | Éradication guidée par l'arn du virus jc humain et d'autres polyomavirus |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20170333572A1 (fr) |
| EP (1) | EP3212795A4 (fr) |
| CN (2) | CN107406854B (fr) |
| AU (1) | AU2015338993B2 (fr) |
| CA (1) | CA2967990C (fr) |
| MA (1) | MA40880A (fr) |
| MX (1) | MX2017005672A (fr) |
| RU (1) | RU2747722C2 (fr) |
| WO (1) | WO2016070070A1 (fr) |
| ZA (1) | ZA201703163B (fr) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066438A2 (fr) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Évaluation et amélioration de la spécificité de clivage des nucléases |
| EP2841572B1 (fr) | 2012-04-27 | 2019-06-19 | Duke University | Correction génétique de gènes ayant subi une mutation |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| US10676726B2 (en) | 2015-02-09 | 2020-06-09 | Duke University | Compositions and methods for epigenome editing |
| WO2017066497A2 (fr) | 2015-10-13 | 2017-04-20 | Duke University | Ingénierie génomique avec systèmes crispr de type i dans des cellules eucaryotes |
| WO2017070632A2 (fr) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Éditeurs de nucléobases et leurs utilisations |
| US12214054B2 (en) | 2015-11-30 | 2025-02-04 | Duke University | Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use |
| CN108473527A (zh) | 2015-12-09 | 2018-08-31 | 切除生物治疗公司 | 用于消除免疫抑制疗法期间jc病毒激活和pml(进行性多灶性白质脑病)风险的基因编辑方法和组合物 |
| US20190038770A1 (en) * | 2016-01-25 | 2019-02-07 | Excision Biotherapeutics,Inc. | Rna guided eradication of human jc virus and other polyomaviruses |
| EP3443081A4 (fr) | 2016-04-13 | 2019-10-30 | Duke University | Répresseurs à base de crispr/cas9 pour inactiver des cibles géniques in vivo et procédés d'utilisation |
| WO2017196768A1 (fr) * | 2016-05-09 | 2017-11-16 | President And Fellows Of Harvard College | Arn-guides à auto-ciblage utilisés dans un système crispr |
| RU2018144745A (ru) * | 2016-06-01 | 2020-07-09 | Эксижн Биотерапьютикс, Инк. | Композиции и способы лечения, направленные на литические и лизогенные вирусы |
| JP7490211B2 (ja) | 2016-07-19 | 2024-05-27 | デューク ユニバーシティ | Cpf1に基づくゲノム編集の治療適用 |
| WO2018027078A1 (fr) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Éditeurs de nucléobases d'adénosine et utilisations associées |
| AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (fr) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation d'acides aminés non naturels dans des protéines au moyen de l'édition de bases |
| KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| WO2018119359A1 (fr) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Édition du gène récepteur ccr5 pour protéger contre l'infection par le vih |
| KR20190123328A (ko) | 2017-03-09 | 2019-10-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 암 백신 |
| WO2018165504A1 (fr) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression de la douleur par édition de gène |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| EP3658573A1 (fr) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Procédés et compositions pour l'évolution d'éditeurs de bases à l'aide d'une évolution continue assistée par phage (pace) |
| EP3676376B1 (fr) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | Éditeurs de bases à haut rendement comprenant une gam |
| CA3082251A1 (fr) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Utilisations d'editeurs de bases adenosine |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| US12509492B2 (en) | 2018-01-19 | 2025-12-30 | Duke University | Genome engineering with CRISPR-Cas systems in eukaryotes |
| WO2019226953A1 (fr) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Éditeurs de bases et leurs utilisations |
| EP3820495A4 (fr) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | Modificateurs d'arn épigénétiques programmables par arn et leurs utilisations |
| WO2020092453A1 (fr) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Éditeurs de nucléobases comprenant geocas9 et utilisations associées |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| WO2020191241A1 (fr) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Procédés et compositions pour l'édition de séquences nucléotidiques |
| TWI887234B (zh) | 2019-04-14 | 2025-06-21 | 美國公爵大學 | 治療杜興氏(duchenne)肌肉失養症之大型突變熱點之aav載體介導之刪除 |
| WO2020214842A1 (fr) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Éditeurs de base d'adénine présentant des effets hors cible réduits |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| JP2022554417A (ja) * | 2019-11-11 | 2022-12-28 | テンプル・ユニバーシティ-オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | ポリオーマjc感染の阻害剤としてのcrispr/cas9システム |
| CA3177481A1 (fr) | 2020-05-08 | 2021-11-11 | David R. Liu | Methodes et compositions d'edition simultanee des deux brins d'une sequence nucleotidique double brin cible |
| CN112322587A (zh) * | 2020-09-17 | 2021-02-05 | 杭州市第一人民医院 | 一种带Cas9基因的人源可诱导多能干细胞系、构建方法、鉴定方法及应用 |
| RU2747820C1 (ru) * | 2020-11-30 | 2021-05-14 | Федеральное бюджетное учреждение науки «Центральный научно-исследовательский институт эпидемиологии» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ЦНИИ Эпидемиологии Роспотребнадзора) | Система CRISPR-Cas для выявления ДНК вируса Джона Каннингема (JCPyV) в ультранизких концентрациях |
| RU2747819C1 (ru) * | 2020-11-30 | 2021-05-14 | Федеральное бюджетное учреждение науки «Центральный научно-исследовательский институт эпидемиологии» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ЦНИИ Эпидемиологии Роспотребнадзора) | Способ получения препарата рибонуклеопротеинового комплекса CRISPR/Cas и препарат для выявления ДНК вируса Джона Каннингема (JCPyV) в ультранизких концентрациях |
| CA3260237A1 (fr) | 2022-06-24 | 2023-12-28 | Tune Therapeutics, Inc. | Compositions, systèmes et procédés de réduction de lipoprotéine de faible densité par répression génique ciblée |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6054312A (en) * | 1997-08-29 | 2000-04-25 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
| AU2002340830A1 (en) * | 2001-05-07 | 2002-11-18 | Tufts University | Peptides that bind to dna and inhibit dna replication, and methods of use |
| WO2007127919A2 (fr) * | 2006-04-28 | 2007-11-08 | Alnylam Pharmaceuticals, Inc. | Compositions et procédés d'inhibition de l'expression d'un gène du virus jc |
| WO2014113493A1 (fr) * | 2013-01-16 | 2014-07-24 | Emory University | Complexes d'acide nucléique cas9 et leurs utilisations |
| WO2014172470A2 (fr) * | 2013-04-16 | 2014-10-23 | Whitehead Institute For Biomedical Research | Procedes de mutation, de modification ou de modulation d'acide nucleique dans une cellule ou chez un mammifere non-humain |
-
2015
- 2015-10-29 MA MA040880A patent/MA40880A/fr unknown
- 2015-10-30 EP EP15855311.5A patent/EP3212795A4/fr not_active Withdrawn
- 2015-10-30 CN CN201580068318.6A patent/CN107406854B/zh not_active Expired - Fee Related
- 2015-10-30 CA CA2967990A patent/CA2967990C/fr active Active
- 2015-10-30 WO PCT/US2015/058351 patent/WO2016070070A1/fr not_active Ceased
- 2015-10-30 RU RU2017115838A patent/RU2747722C2/ru active
- 2015-10-30 MX MX2017005672A patent/MX2017005672A/es unknown
- 2015-10-30 AU AU2015338993A patent/AU2015338993B2/en not_active Ceased
- 2015-10-30 US US15/523,272 patent/US20170333572A1/en not_active Abandoned
- 2015-10-30 CN CN202210155200.9A patent/CN115044570A/zh not_active Withdrawn
-
2017
- 2017-05-08 ZA ZA2017/03163A patent/ZA201703163B/en unknown
-
2022
- 2022-04-22 US US17/727,438 patent/US20230001016A1/en not_active Abandoned
-
2024
- 2024-10-21 US US18/921,813 patent/US20250082778A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201703163B (en) | 2019-03-27 |
| RU2747722C2 (ru) | 2021-05-13 |
| AU2015338993A1 (en) | 2017-05-25 |
| MX2017005672A (es) | 2018-11-09 |
| AU2015338993B2 (en) | 2021-12-09 |
| RU2017115838A3 (fr) | 2018-11-30 |
| WO2016070070A1 (fr) | 2016-05-06 |
| RU2017115838A (ru) | 2018-11-30 |
| CA2967990A1 (fr) | 2016-05-06 |
| HK1247636A1 (zh) | 2018-09-28 |
| US20250082778A1 (en) | 2025-03-13 |
| US20170333572A1 (en) | 2017-11-23 |
| EP3212795A4 (fr) | 2018-06-27 |
| CN115044570A (zh) | 2022-09-13 |
| CA2967990C (fr) | 2024-02-13 |
| CN107406854B (zh) | 2022-03-11 |
| EP3212795A1 (fr) | 2017-09-06 |
| CN107406854A (zh) | 2017-11-28 |
| US20230001016A1 (en) | 2023-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3408392A4 (fr) | Éradication du virus jc humain et d'autres polyomavirus guidée par un arn | |
| IL295358A (en) | Using programmable dna binding proteins to enhance targeted genome modification | |
| ZA201703163B (en) | Rna guided eradication of human jc virus and other polyomaviruses | |
| MA50813A (fr) | Vaccins contre le virus d'epstein-barr | |
| IL269642A (en) | Methods and compositions for enhancing health | |
| EP3309251A4 (fr) | Vecteur viral de parainfluenza de type 2 humain et vaccin | |
| EP2916865A4 (fr) | Mutations de la protéine d'enveloppe du flavivirus affectant le désassemblage du virion | |
| HUE065662T2 (hu) | Készítmények és eljárások betegségek kezelésére | |
| IL258697A (en) | Crispr/cas-related methods and compositions for treating hepatitis b virus | |
| IL244431A0 (en) | Pharmacy methods and preparations for the treatment of hepatitis b virus infection | |
| IL258459A (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
| EP2931891A4 (fr) | Manipulation du génome humain guidée par l'arn | |
| IL260684B (en) | Treatment for modulating gut microbiota | |
| IL240727B (en) | Peptides and compositions for treatment of joint damage | |
| EP3220953A4 (fr) | Compositions et procédés d'utilisation de peptides thérapeutiques en relation avec p53 et de leurs analogues | |
| IL256515A (en) | Therapeutic peptides and methods of use thereof | |
| EP3385273A4 (fr) | Mutant de la protéine l1 du virus du papillome humain de type 58 | |
| GB201404403D0 (en) | Compositions and methods relating to the treatment of diseases | |
| IL248779A0 (en) | Pharmaceutical compositions for treating infectious diseases | |
| EP3313427A4 (fr) | Peptides thérapeutiques et leurs procédés d'utilisation | |
| EP3385274A4 (fr) | Mutant de la protéine l1 du virus du papillome humain de type 11 | |
| SG11201510266SA (en) | Dengue virus vaccine compositions and methods of use thereof | |
| EP3419638A4 (fr) | Compositions et procédés de traitement de maladies infectieuses chroniques | |
| SG11201704942QA (en) | Dengue virus vaccine compositions and methods of use thereof | |
| EP3653638A4 (fr) | Mutant de protéine l1 du type 16 du papillomavirus humain |